Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1933 1
1934 2
1939 1
1944 1
1947 1
1948 2
1949 5
1950 4
1951 9
1952 2
1953 6
1954 4
1955 5
1956 5
1957 4
1958 3
1959 3
1960 13
1961 6
1962 3
1963 9
1964 10
1965 11
1966 11
1967 14
1968 11
1969 11
1970 6
1971 12
1972 15
1973 16
1974 17
1975 25
1976 28
1977 24
1978 24
1979 19
1980 27
1981 25
1982 38
1983 40
1984 42
1985 43
1986 63
1987 41
1988 33
1989 56
1990 65
1991 61
1992 70
1993 59
1994 54
1995 61
1996 67
1997 73
1998 71
1999 72
2000 64
2001 60
2002 67
2003 74
2004 68
2005 75
2006 86
2007 94
2008 92
2009 100
2010 82
2011 97
2012 103
2013 111
2014 114
2015 113
2016 96
2017 110
2018 110
2019 143
2020 128
2021 182
2022 154
2023 119

Text availability

Article attribute

Article type

Publication date

Search Results

3,574 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Yu EY, et al. Among authors: harrison mr. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.
Reply.
Belay B, Frintner MP, Liebhart JL, Lindros J, Harrison M, Dooyema CA, Hassink SG, Cook SR. Belay B, et al. Among authors: harrison m. J Pediatr. 2019 Dec;215:285-286. doi: 10.1016/j.jpeds.2019.08.015. Epub 2019 Sep 26. J Pediatr. 2019. PMID: 31564428 Free PMC article. No abstract available.
Fifteen compelling open questions in plant cell biology.
Roeder AHK, Otegui MS, Dixit R, Anderson CT, Faulkner C, Zhang Y, Harrison MJ, Kirchhelle C, Goshima G, Coate JE, Doyle JJ, Hamant O, Sugimoto K, Dolan L, Meyer H, Ehrhardt DW, Boudaoud A, Messina C. Roeder AHK, et al. Among authors: harrison mj. Plant Cell. 2022 Jan 20;34(1):72-102. doi: 10.1093/plcell/koab225. Plant Cell. 2022. PMID: 34529074 Free PMC article. Review.
Prior Authorization.
Harrison MB. Harrison MB. Neurology. 2023 Aug 30:10.1212/WNL.0000000000207790. doi: 10.1212/WNL.0000000000207790. Online ahead of print. Neurology. 2023. PMID: 37648531 No abstract available.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A. Tykodi SS, et al. Among authors: harrison mr. J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844. J Immunother Cancer. 2022. PMID: 35210307 Free PMC article. Clinical Trial.
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Hirsch L, et al. Among authors: harrison mr. JAMA Oncol. 2021 Dec 1;7(12):1815-1823. doi: 10.1001/jamaoncol.2021.4544. JAMA Oncol. 2021. PMID: 34673916 Free PMC article.
Sex in the Time of COVID-19.
Harrison M. Harrison M. J Rheumatol. 2023 Jul 15:jrheum.2023-0444. doi: 10.3899/jrheum.2023-0444. Online ahead of print. J Rheumatol. 2023. PMID: 37453740
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators. Motzer RJ, et al. Among authors: harrison mr. Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427204 Free PMC article. Clinical Trial.
Pioneering the developmental frontier.
Larson ED, Marsh AJ, Harrison MM. Larson ED, et al. Among authors: harrison mm. Mol Cell. 2021 Apr 15;81(8):1640-1650. doi: 10.1016/j.molcel.2021.02.020. Epub 2021 Mar 8. Mol Cell. 2021. PMID: 33689750 Free PMC article. Review.
3,574 results